Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06926868 |
| Title | A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) |
| Acronym | IZABRIGHT-Breast01 |
| Recruitment | Not yet recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Bristol-Myers Squibb |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA | SWE | ROU | POL | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BRA | AUT | AUS | ARG |